Share Price Momentum

Showing 2858 articles
Business

AbCellera Biologics: A Tale of Two Valuations Amid Steep Share Decline

Shares of antibody discovery firm AbCellera Biologics plunged 16.8% last week, reigniting debate over its true worth. While a discounted cash flow model suggests deep undervaluation, its sky-high price-to-sales ratio paints a starkly different picture, leaving investors to navigate conflicting signals in a volatile biotech market.

Business

NETSTREIT's Rally Raises Valuation Questions: Is the REIT Still a Buy?

NETSTREIT Corp. (NYSE: NTST) has delivered impressive shareholder returns over the past year, significantly outpacing its longer-term performance. As the stock hovers near $19, investors and analysts are debating whether its current price fully reflects the fundamentals of this necessity-based retail REIT or if momentum has gotten ahead of value.